Patricia Ares-Romero, MD, FASAM

Articles by Patricia Ares-Romero, MD, FASAM

The Positive Impact of Prescription Digital Therapeutics: Insights From Patricia Ares-Romero, MD

November 21st 2025

Presenters at the Southern Florida Psychiatry Conference shared how prescription digital therapeutics can greatly improve patient outcomes.

Integrated Care and Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Electroconvulsive Therapy for Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Traditional Classes of Antidepressant Therapies

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Frontline Psychotherapy for Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Treatment-Resistant Depression: Financial Support for Esketamine Therapy

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Incorporating Esketamine into Practice for Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Getting Certified to Administer Esketamine for Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Treatment-Resistant Depression: Administering Esketamine to Patients

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

REMS Safety Program for Esketamine in Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Response to Esketamine Therapy for Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Monitoring Patients on Esketamine Therapy for Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Esketamine for Treatment-Resistant Depression: Patient Selection Criteria

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Intranasal Esketamine for Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Current Guidelines for Managing Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

IV Ketamine for Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Prevalence of Treatment-Resistant Depression

BySteven P. Levine, MD,Angelos Halaris, MD, PhD, APA, ACNP, CINP,Lisa Harding, MD,Patricia Ares-Romero, MD, FASAM

July 15th 2021

Custom ViewPoints Video Program

Latest Updated Articles

Prevalence of Treatment-Resistant Depression
July 15th 2021
IV Ketamine for Treatment-Resistant Depression
July 15th 2021
Esketamine for Treatment-Resistant Depression: Patient Selection Criteria
July 15th 2021
Getting Certified to Administer Esketamine for Treatment-Resistant Depression
July 15th 2021
Treatment-Resistant Depression: Administering Esketamine to Patients
July 15th 2021
Electroconvulsive Therapy for Depression
July 15th 2021

Patricia Ares-Romero, MD, FASAM

Articles by Patricia Ares-Romero, MD, FASAM

The Positive Impact of Prescription Digital Therapeutics: Insights From Patricia Ares-Romero, MD

Integrated Care and Treatment-Resistant Depression

Electroconvulsive Therapy for Depression

Traditional Classes of Antidepressant Therapies

Frontline Psychotherapy for Depression

Treatment-Resistant Depression: Financial Support for Esketamine Therapy

Incorporating Esketamine into Practice for Treatment-Resistant Depression

Getting Certified to Administer Esketamine for Treatment-Resistant Depression

Treatment-Resistant Depression: Administering Esketamine to Patients

REMS Safety Program for Esketamine in Treatment-Resistant Depression

Response to Esketamine Therapy for Treatment-Resistant Depression

Monitoring Patients on Esketamine Therapy for Treatment-Resistant Depression

Esketamine for Treatment-Resistant Depression: Patient Selection Criteria

Intranasal Esketamine for Treatment-Resistant Depression

Current Guidelines for Managing Treatment-Resistant Depression

IV Ketamine for Treatment-Resistant Depression

Prevalence of Treatment-Resistant Depression

Latest Updated Articles

Trending on Psychiatric Times

Positive Topline Results From Phase 3 Emerge Study of DT120 ODT in Major Depressive Disorder

FDA Issues CRL for Cytisinicline for Smoking Cessation in Adults

Evaluating Transdermal Asenapine in Schizophrenia

Empowering Patients and Expanding Formulation Options in Schizophrenia Care